Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzo[D]Thiazole SCHEMBL28719601 | 0.92 | ALDH1A1 (0.76) | ALDH1A1HSD17B10RAB9ANPC1L3MBTL1 | |
| Benzo[D]Thiazole SCHEMBL28745461 | 0.86 | ALDH1A1 (0.61) | ALDH1A1HSD17B10RAB9ANPC1L3MBTL1 | |
| Benzo[D]Thiazole SCHEMBL27900622 | 0.86 | ALDH1A1 (0.86) | ALDH1A1HSD17B10RAB9ANPC1L3MBTL1 | |
| Benzo[D]Thiazole SCHEMBL28708292 | 0.86 | ALDH1A1 (0.86) | ALDH1A1HSD17B10RAB9ANPC1L3MBTL1 | |
| Benzo[D]Thiazole SCHEMBL11575843 | 0.84 | ALDH1A1 (0.91) | ALDH1A1HSD17B10RAB9ANPC1L3MBTL1 | |
| Benzo[D]Thiazole SCHEMBL31388426 | 0.84 | — | — | |
| Benzo[D]Thiazole SCHEMBL10847268 | 0.84 | — | — | |
| Benzo[D]Thiazole SCHEMBL8430 | 0.84 | — | — | |
| Benzo[D]Thiazole SCHEMBL451685 | 0.84 | — | — | |
| Benzo[D]Thiazole SCHEMBL900814 | 0.84 | ALDH1A1 (1.00) | ALDH1A1HSD17B10RAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133235-B2 | Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders | OCERA THERAPEUTICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| CN-101528765-B | Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders | OCERA THERAPEUTICS INC | 2015-04-22 | — | — | CN | disclosed |
| EP-2054429-B1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | TRANZYME PHARMA INC (CA) | 2013-11-06 | — | — | EP | disclosed |
| EP-2431380-A2 | Macrocyclic antagonist of the motilin receptor for treatment of gastrointestinal dysmotility disorders | Tranzyme Pharma, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| CN-101528765-A | Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders | TRANZYME PHARMA INC (US) | 2009-09-09 | — | — | CN | disclosed |
| EP-2054429-A2 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | Tranzyme Pharma, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008033328-A2 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | TRANZYME PHARMA, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MLNR, GIPR, GPR39 | ALDH1A1 4480/4885HSD17B10 3528/4885RAB9A 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.